David B. Ring

1.6k total citations
30 papers, 1.3k citations indexed

About

David B. Ring is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, David B. Ring has authored 30 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Radiology, Nuclear Medicine and Imaging, 21 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in David B. Ring's work include Monoclonal and Polyclonal Antibodies Research (23 papers), Glycosylation and Glycoproteins Research (17 papers) and Toxin Mechanisms and Immunotoxins (6 papers). David B. Ring is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (23 papers), Glycosylation and Glycoproteins Research (17 papers) and Toxin Mechanisms and Immunotoxins (6 papers). David B. Ring collaborates with scholars based in United States, Switzerland and Japan. David B. Ring's co-authors include Tyson R. Kinnick, Kirk W. Johnson, Stephen D. Harrison, Erik J. Henriksen, Louis M. Weiner, R. Katherine Alpaugh, M J Bjorn, John M. Nuss, Allan S. Wagman and Arthur E. Frankel and has published in prestigious journals such as The Journal of Immunology, Diabetes and International Journal of Cancer.

In The Last Decade

David B. Ring

30 papers receiving 1.2k citations

Peers

Countries citing papers authored by David B. Ring

Since Specialization

Citations

This map shows the geographic impact of David B. Ring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Ring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Ring more than expected).

Fields of papers citing papers by David B. Ring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Ring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Ring. The network helps show where David B. Ring may publish in the future.

Co-authorship network of co-authors of David B. Ring

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Ring. A scholar is included among the top collaborators of David B. Ring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Ring. David B. Ring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitors 2019 ·Bioorganic & Medicinal Chemistry Letters ·Savithri Ramurthy, Keith Pfister, (unknown), Sean P. Brown, (unknown), Manoj C. Desai, Eric Fang, Barry H. Levine, Simon C. Ng, John M. Nuss, David B. Ring, Cynthia M. Shafer, Wei Shu, Sharadha Subramanian, Allan S. Wagman, Haixia Wang, Dirksen E. Bussiere	11
2	Chemical conjugation of a novel antibody-interleukin 2 immunoconjugate against c-erbB-2 product. 2000 ·PubMed ·(unknown), (unknown), (unknown), David B. Ring, C S Kwok	2
3	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Vitro in Acutely and Persistently Infected Human CD4+ Mononuclear Cells Expressing Murine and Humanized Anti-Human Immunodeficiency Virus Type 1 Tat Single-Chain Variable Fragment Intrabodies 1999 ·Human Gene Therapy ·Abner M. Mhashilkar, (unknown), (unknown), (unknown), Saskia Boisot, (unknown), Carla Y. Pumphrey, Xuguang Li, (unknown), David B. Ring, Urban Ramstedt, Wayne A. Marasco	34
4	Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment 1997 ·Cancer Immunology Immunotherapy ·John I. Clark, R. Katherine Alpaugh, Margaret von Mehren, (unknown), Julie R. Gralow, Martin A. Cheever, David B. Ring, Louis M. Weiner	19
5	Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fcγ RIII 1996 ·Cancer Immunology Immunotherapy ·Louis M. Weiner, R. Katherine Alpaugh, (unknown), Gregory P. Adams, David B. Ring, (unknown)	17
6	In VitroTumor Growth Inhibition by Bispecific Antibodies to Human Transferrin Receptor and Tumor-Associated Antigens Is Augmented by the Iron Chelator Deferoxamine 1996 ·Clinical Immunology and Immunopathology ·(unknown), (unknown), John C. Reeder, David B. Ring	10
7	Murine Bispecific Antibody 1A10 Directed to Human Transferrin Receptor and a 42-kDa Tumor-Associated Glycoprotein 1996 ·Clinical Immunology and Immunopathology ·(unknown), (unknown), John C. Reeder, David B. Ring	3
8	Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. 1995 ·PubMed ·Louis M. Weiner, Joseph I. Clark, Michael P. Davey, (unknown), (unknown), David B. Ring, R. Katherine Alpaugh	112
9	Clinical Development of 2B1, a Bispecific Murine Monoclonal Antibody Targeting c-erbB-2 and FcγRIII 1995 ·Journal of Hematotherapy ·Louis M. Weiner, Joseph I. Clark, David B. Ring, R. Katherine Alpaugh	48
10	High-Affinity Monoclonal Antibodies against P-Glycoprotein 1995 ·Clinical Immunology and Immunopathology ·(unknown), Joe Wrin, John C. Reeder, David Liu, David B. Ring	20
11	Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens 1994 ·Cancer Immunology Immunotherapy ·David B. Ring, (unknown), (unknown), John C. Reeder	5
12	Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. 1993 ·The Journal of Immunology ·Louis M. Weiner, (unknown), (unknown), Antony Godwin, Gregory P. Adams, (unknown), David B. Ring, R. Katherine Alpaugh	40
13	In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III. 1992 ·PubMed ·(unknown), (unknown), (unknown), David B. Ring	25
14	Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2 1991 ·Molecular Immunology ·David B. Ring, Robin Clark, (unknown)	23
15	Selection of hybrid hybridomas by flow cytometry using a new combination of fluorescent vital stains 1991 ·Journal of Immunological Methods ·(unknown), (unknown), David B. Ring	26
16	Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. 1990 ·PubMed ·Yu Yin, Jennie R. Crews, Kevin D. Cooper, Sundaram Ramakrishnan, (unknown), David S. Leslie, (unknown), (unknown), C. Boyer, David B. Ring	19
17	Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells 1989 ·International Journal of Cancer ·Cinda M. Boyer, Michael J. Borowitz, Kenneth S. McCarty, R. B. Kinney, (unknown), Deborah V. Dawson, David B. Ring, Robert C. Bast	23
18	Targeted cytotoxic cells as a novel form of cancer immunotherapy 1988 ·Molecular Immunology ·David M. Segal, María Garrido, Pilar Pérez, Julie A. Titus, David A. Winkler, David B. Ring, Andreas Kaubisch, John R. Wunderlich	19
19	Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. 1985 ·PubMed ·Arthur E. Frankel, David B. Ring, (unknown), (unknown)	78
20	Selection of monoclonal antibodies for the development of breast cancer selective immunotoxins 1984 ·Federation Proceedings ·Arthur E. Frankel, David B. Ring, D A Kaplan, M J Bjorn	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact